Zarxio FDA Approval History
Last updated by Judith Stewart, BPharm on Jan 27, 2021.
FDA Approved: Yes (First approved March 6, 2015)
Brand name: Zarxio
Generic name: filgrastim-sndz
Dosage form: Injection
Company: Sandoz Inc.
Treatment for: Neutropenia Associated with Chemotherapy
Zarxio (filgrastim-sndz) is a leukocyte growth factor biosimilar to the reference product Neupogen, indicated for the treatment of neutropenia associated with chemotherapy.
Development timeline for Zarxio
| Date | Article |
|---|---|
| Mar 6, 2015 | Approval FDA Approves First Biosimilar Product Zarxio (filgrastim-sndz) |
| Jan 7, 2015 | Sandoz Biosimilar Filgrastim Recommended for Approval |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
